Navigation Links
Pitt treats gum disease by bringing needed immune cells to inflamed tissue
Date:11/1/2013

PITTSBURGH, Nov. 1, 2013 The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh. Their findings, published this week in the early online version of the Proceedings of the National Academy of Sciences, offer a new therapeutic paradigm for a condition that afflicts 78 million people in the U.S. alone.

Periodontal disease currently is treated by keeping oral bacteria in check with daily brushing and flossing as well as regular professional deep cleaning with scaling and root planing, which remove tartar above and below the gum line. In some hard-to-treat cases, antibiotics are given. These strategies of mechanical tartar removal and antimicrobial delivery aim to reduce the amount of oral bacteria on the tooth surface, explained co-author and co-investigator Charles Sfeir, D.D.S., Ph.D., director, Center for Craniofacial Regeneration and associate professor, Departments of Periodontics and Oral Biology, Pitt's School of Dental Medicine.

"Currently, we try to control the build-up of bacteria so it doesn't trigger severe inflammation, which could eventually damage the bone and tissue that hold the teeth in place," Dr. Sfeir said. "But that strategy doesn't address the real cause of the problem, which is an overreaction of the immune system that causes a needlessly aggressive response to the presence of oral bacteria. There is a real need to design new approaches to treat periodontal disease."

In the healthy mouth, a balance exists between bacteria and the immune system response to forestall infection without generating inflammation, said senior author Steven Little, Ph.D., associate professor and chair of the Department of Chemical and Petroleum Engineering, Pitt's Swanson School of Engineering. But in many people, a chronic overloa
'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-720-2058
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Icy therapy spot treats cancer in the lung
2. Pressure cooker on steroids treats human waste
3. Largest therapy trial worldwide: Psychotherapy treats anorexia effectively
4. Moderate exercise not only treats, but prevents depression
5. Parkinsons disease stopped in animal model
6. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Common North American frog identified as carrier of deadly amphibian disease
9. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
10. Genetic research develops tools for studying diseases, improving regenerative treatment
11. Researchers discover novel therapy for Crohns disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... BGI the world,s largest genomic organization and Johns ... for the synthetic yeast project (SC2.0 PROJECT), an ambitious ... the yeast genome. This project was initiated by JHU ... In addition to the research collaboration of SC2.0 ...
... people in North America are afflicted with dystonia, a ... Patients with generalized dystonia grapple with involuntary muscle spasms ... sometimes painful postures. Although cognition, intelligence and life span ... impact on quality of life, as its victims frequently ...
... are most likely to become obese by examining their mothers, ... Montreal study published in the Archives of Pediatric and ... and is also influenced by a complex tangle of influencing ... improve the social and medical services we offer to mothers ...
Cached Biology News:BGI announces collaboration with Johns Hopkins University on synthetic yeast project 2BGI announces collaboration with Johns Hopkins University on synthetic yeast project 3University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3Future obesity may be predicted at 3.5 years of age 2
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
(Date:8/26/2015)... ... , ... PRC Clinical, a Clinical Trial Management Expert CRO, will ... southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors ... , Stem Cell Meeting on the Mesa on October 7-9 ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Actavis Group, the,international generic pharmaceuticals company, today ... U.S. Food & Drug Administration to market,Fentanyl ... begin,immediately. Fentanyl Transdermal System is the ... 25, 50, 75 and 100 mcg/hour strengths.,Fentanyl ...
... (Euronext: AMT), a leader in the field of human ... results for the first,six months of 2007 on Wednesday, ... To discuss these results, the Company will conduct ... +31-800-949-4517 (toll free); US Dial In:,+1-866-291-4166 (toll free); UK ...
... Company confirms commercial expression levels of ... status of native Apo AI -, CALGARY, ... biotechnology company developing a portfolio of therapeutic,proteins for ... on July 12, 2007 announcing that the Company ...
Cached Biology Technology:Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: